Investor presentation March – April 2026 Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to id ...

Core Insights - The company reported strong growth across its business units, with a notable 7.9% underlying growth in Orthopedics, marking the strongest quarterly growth in over two years [2] - Management emphasized the importance of CORI deployment, with "Other recon" growing by 40.8% and a significant increase in knee growth in accounts where CORI is established [1] - The company achieved a fourth-quarter revenue of $1.7 billion, reflecting a 6.2% underlying growth and an 8.3% reported growth, aided by foreign exchange [4] Financial Performance - Full-year revenue for 2025 reached $6.2 billion, up 5.3% on an underlying basis and 6.1% reported, with segment growth reported as 5.1% in Orthopedics, 5.2% in Sports Medicine and ENT, and 5.6% in Advanced Wound Management [8] - Adjusted EPS rose by 21% to $1.02, supported by a $500 million buyback completed in the second half of 2025 [10] - Free cash flow increased by 52.5% to $840 million, driven by improved working capital performance and lower restructuring costs [10] Growth Drivers - The U.S. revenue grew by 5.6%, with other established markets rising by 7.2% and emerging markets increasing by 6.4% [3] - Sports Medicine and ENT grew by 7.3% in Q4, with joint repair surpassing $1 billion in annual revenue for the first time [6] - Advanced Wound Management grew by 2.8% in the quarter, with Advanced Wound Devices performing particularly well [7] Strategic Initiatives - The company plans to expand its shoulder portfolio through the acquisition of Integrity Orthopaedics, with total consideration up to $450 million [16] - Management expects around 6% organic revenue growth in 2026, with profit growth anticipated to outpace revenue growth [12] - The company aims for a medium-term organic revenue CAGR of 6% to 7% and trading profit CAGR of 9% to 10% under its RISE strategy [18] Market Outlook - Management anticipates a $60 million impact from tariffs in 2026, up from $17 million in 2025, and a $20 million to $40 million incremental impact from changes to wound reimbursement [13] - Sales in greater China for 2026 are expected to be similar to 2025, with anticipated challenges from AET and ENT VBPs [15] - The company expects first-half revenue growth of approximately 4.5% to 5% and second-half growth of 7.5% to 8% [14]

Financial Data and Key Metrics Changes - The company reported a strong finish to 2025, achieving underlying revenue growth of 5.3% and free cash flow of $840 million, a 52.5% increase year-on-year [1][3] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] - Adjusted earnings per share grew by 21% to $1.02, driven by a $500 million share buyback [18][19] Business Line Data and Key Metrics Changes - Orthopedics grew by 5.1%, Sports Medicine and ENT by 5.2%, and Advanced Wound Management by 5.6%, all on an underlying basis [15][16] - The joint repair business surpassed $1 billion in revenue for the first time, driven by products like REGENETEN and Q-FIX [11][12] - Advanced Wound Management grew 2.8% in Q4, with Advanced Wound Care growing 4.4% [13][14] Market Data and Key Metrics Changes - U.S. growth was 5.6%, other established markets 7.2%, and emerging markets 6.4%, with underlying growth excluding China at 7.2% [7][16] - The company expects continued growth in orthopedics, sports medicine, and Advanced Wound Management, particularly in AWC and AWD [27][28] Company Strategy and Development Direction - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][34] - The company plans to increase R&D investment and maintain a robust product launch pipeline, with expectations of launching 16 new products in 2026 [43][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth in 2026, with trading profit growth expected to be around 8% [20][29] - The impact of China VBP on joint repair is expected to be less significant moving forward, with management anticipating a bounce in sports business in China [72][75] - The company aims to maintain a focus on organic growth and capital allocation towards high-value clinical segments [68][69] Other Important Information - The company achieved a 15-fold increase in free cash flow and a 170 basis points increase in ROIC from 6.6% to 8.3% [6][25] - The company expects to face extraordinary headwinds in 2026, including inventory revaluation and changes to reimbursement in the U.S. AWM business [20][21] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and expectations for market growth? - Management indicated that 2026 revenue growth is expected to be around 6%, with contributions from all business units and innovation driving growth [48][49] Question: What is the expected phasing of revenue growth through the quarters? - Management expects Q1 to be softer due to one fewer trading day, with growth in the first half around 4.5%-5% and stronger growth in Q3 and Q4 [53][54] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and they expect a bounce in sports business while AET and ENT will have a limited negative impact [64][75]

Financial Performance - The company reported a strong finish to 2025, achieving underlying revenue growth of 5.3% and free cash flow of $840 million, a 52.5% increase year-on-year [1][3][15] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] - Adjusted earnings per share grew by 21% to $1.02, driven by a $500 million share buyback [18][19] Business Unit Performance - Orthopedics grew 7.9% on an underlying basis, with strong performance in hips and trauma, while U.S. knee growth improved following the launch of LEGION MS [7][8][10] - Sports medicine and ENT grew 7.3%, with joint repair surpassing $1 billion in revenue for the first time, driven by REGENETEN and Q-FIX [11][12] - Advanced Wound Management grew 2.8%, with Advanced Wound Care growing 4.4% [13][15] Market Performance - U.S. growth was 5.6%, with other established markets at 7.2% and emerging markets at 6.4% [7] - Excluding China, underlying growth was 7.2%, indicating strong performance across various regions [16] Company Strategy and Industry Competition - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][35] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth for 2026, with trading profit growth expected to be around 8% [20][29] - The impact of China VBP on joint repair is expected to be less significant moving forward, with management anticipating a bounce in sports business in China [72][75] Other Important Information - The company achieved a 15-fold increase in free cash flow and a 170 basis points increase in ROIC to 8.3% [6][25] - The company plans to maintain a dividend ratio of 35%-40% and consider buybacks subject to leverage targets [27] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and expectations for market growth? - Management indicated that 2026 revenue growth is expected to be around 6%, with innovation contributing significantly to this growth [48][49] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and the impact of VBP will be less significant moving forward [64][75] Question: How does M&A impact bottom line growth? - Management emphasized that M&A, such as the acquisition of Integrity, is aimed at scaling in areas of strength and is expected to be accretive in the long term [68][69]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported underlying revenue growth of 5.3%, with all three business units growing by over 5% [1][15] - Free cash flow increased to $840 million, a 52.5% year-on-year growth, enabling a $500 million share buyback program [3][26] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] Business Line Data and Key Metrics Changes - Orthopedics grew 7.9% on an underlying basis, with strong performance in hips and trauma, while U.S. knee growth improved following the launch of LEGION MS [8][9] - Sports medicine and ENT grew 7.3%, driven by double-digit growth in joint repair, surpassing $1 billion in revenue for the first time [12][13] - Advanced Wound Management grew 2.8%, with Advanced Wound Care growing 4.4% [14][15] Market Data and Key Metrics Changes - U.S. growth was 5.6%, other established markets grew 7.2%, and emerging markets grew 6.4% [7] - Excluding China, underlying growth was 7.2%, indicating strong performance in other markets despite challenges in China [16][17] Company Strategy and Development Direction - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][35] - The company aims for more than 20% margin in orthopedics by 2030, supported by initiatives like the Ortho360 operating model [3][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth for 2026, with trading profit growth expected to be around 8% [4][28] - The impact of China VBP is expected to be less significant in 2026, with management anticipating a flat performance in greater China sales compared to 2025 [70][73] - The company is focused on innovation, with over 60% of growth in 2025 coming from products launched in the last five years [2][16] Other Important Information - The company achieved a 240 basis points trading margin expansion from 17.3% in 2022 to 19.7% in 2025, despite facing headwinds from VBP in China and inflation [5][19] - The company plans to maintain a dividend ratio of 35%-40% and consider buybacks subject to leverage targets [27] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and the impact of new product launches? - Management indicated that growth will be driven by multiple sources, with innovation contributing significantly, and expects around 6% growth for 2026 [48][49] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and they expect a balanced portfolio to drive growth without the previous VBP drag [63][74] Question: How does M&A impact bottom line growth? - Management emphasized that M&A, like the acquisition of Integrity, is aimed at scaling in areas of strength and will complement existing products, enhancing overall growth potential [66][68]

Core Viewpoint - The Japanese automotive market, historically dominated by local brands, is witnessing a significant shift as foreign electric vehicle (EV) manufacturers are beginning to penetrate this previously closed market, driven by the slow electrification of domestic brands and changing consumer preferences [4][5][6]. Group 1: Market Overview - Japan's automotive market has long been considered one of the most challenging for foreign brands, with local manufacturers holding over 90% market share [4]. - In 2025, Japan's total new car sales are projected to reach 4.5658 million units, with a 3.3% year-on-year increase, while foreign brands are starting to gain traction [5]. - The electric vehicle market in Japan is still in its infancy, with only 60,677 EVs sold in 2025, representing a mere 1.6% of total vehicle sales [5]. Group 2: Foreign Brands' Entry - The Japanese Imported Automobile Association reported a 7% increase in non-local brand vehicle sales in 2025, totaling 243,129 units, with pure electric imports surging by 26% to a record 30,513 units [6]. - Hyundai is making a comeback in Japan, with a 89% increase in sales in 2025, reaching 1,169 units, driven by the introduction of several electric models [8][10]. - Tesla's sales in Japan saw a remarkable 90% increase in 2025, reaching approximately 10,600 units, attributed to a shift in sales strategy towards physical stores [12][14]. Group 3: Chinese Brands' Expansion - BYD entered the Japanese market in 2023 and aims to establish 100 dedicated stores by 2025, achieving a 62% sales increase to 3,870 units in 2025 [15][18]. - Other Chinese brands, such as Zeekr and GAC, are also planning to enter the Japanese market, with unique offerings tailored to local consumer preferences [19][21]. Group 4: Domestic Brands' Response - Japanese automakers are not standing still; Toyota's new EV model bZ4X received over 10,000 orders within three months of its launch in late 2025, becoming the top-selling EV in Japan [24][27]. - Nissan and Honda are also launching new EV models to compete with foreign brands, with Nissan's new LEAF and Honda's N-ONE e: entering the market [27][28].

Core Viewpoint - The Zacks Foreign Auto Industry outlook remains cautious, with varying growth prospects across key markets, particularly in China, Europe, Japan, and India, influenced by policy changes and consumer confidence [1][4][5][7]. Industry Overview - The Zacks Automotive – Foreign industry encompasses the design, manufacturing, and sale of vehicles and components, heavily influenced by economic conditions and business cycles [3]. - Key manufacturing countries include China, Japan, Germany, and India, with a significant shift towards electric and autonomous vehicles driven by stricter emission regulations and technological advancements [3]. Factors Influencing Industry Dynamics - **China**: After record sales in 2025, growth is expected to slow in 2026 due to reduced policy support for new energy vehicles (NEVs) and fragile consumer confidence [4]. - **Europe**: Modest growth of about 2.5% in 2025 is anticipated to continue, but profitability remains a concern due to a shift towards lower-margin mass-market and EV models [5]. - **Japan**: The market showed a 3.3% sales increase in 2025, with a positive outlook for 2026 supported by tax reductions, although prices limit a full recovery to pre-pandemic levels [6]. - **India**: The market grew by 5% in 2025, driven by government tax cuts improving affordability, with a positive sentiment expected to sustain demand momentum [7][8]. Industry Performance and Valuation - The Zacks Automotive – Foreign industry ranks 184, placing it in the bottom 25% of Zacks industries, reflecting a negative earnings outlook with a 62.6% decline in earnings estimates for 2026 [9][10]. - The industry has underperformed compared to the broader Auto, Tires, and Truck sector and the S&P 500, with an 11% increase over the past year compared to 16% and 14% for the sector and S&P 500, respectively [12]. - The industry is currently trading at an EV/EBITDA ratio of 10.48X, significantly lower than the S&P 500's 18.90X and the sector's 27.29X [15]. Stock Recommendations - **XPeng Inc. (XPEV)**: Notable growth with a 126% increase in vehicle deliveries in 2025, expanding internationally and investing in future technologies [19][20][21]. - **Nissan Motor (NSANY)**: Undergoing a strategic reset with cost-cutting measures and an electrification push, expecting significant improvements in sales and profitability by fiscal 2026 [24][25][26]. - **Mazda Motor (MZDAY)**: Focusing on hybrids while delaying its major EV rollout, with a strategy to balance emissions reduction and consumer preferences, expecting substantial growth in sales and earnings by fiscal 2027 [29][30][31].

Industry Overview - The auto industry is transforming with electric vehicles (EVs) and autonomous vehicles (AVs) becoming mainstream, challenging traditional automakers and increasing competition from startups [2] - Government support through subsidies and incentives is accelerating the shift to electric mobility, alongside advancements in battery technology and charging infrastructure [3] EV Market Dynamics - Global EV sales increased by 25% in 2024, reaching 17.8 million units, and are projected to hit 21.3 million in 2025, representing nearly 25% of all auto sales [4] - By 2030, annual EV sales could exceed 40.1 million units, with Europe expected to have 63% of sales from EVs, and China already surpassing 50% [5] AV Market Growth - The global AV market, valued at approximately $106 billion in 2021, is projected to grow to over $2.3 trillion by 2030, driven by advancements in AI, machine learning, and connectivity [6] Investment Opportunities - The EV and AV sectors present significant growth and innovation potential for investors, with recommended stocks including QuantumScape Corp. (QS), Nissan Motor Co. (NSANY), and Blue Bird Corporation (BLBD) [7] Company Highlights: Blue Bird Corporation - Blue Bird is transitioning from a traditional school bus manufacturer to a leader in clean transportation, with over 22,000 alternative-powered buses in operation [9] - The company is benefiting from government incentives, with more than half of its sales now from non-diesel vehicles, and has expanded into infrastructure support for fleet transitions [10] - Recent innovations include the launch of an electric step van and a propane-powered chassis, enhancing its product offerings [11] Company Highlights: QuantumScape - QuantumScape is recognized as a solid-state battery pioneer, recently partnering with Volkswagen to accelerate battery development and establish a pilot production line [13] - The company has improved its manufacturing process, increasing efficiency significantly, and is moving closer to mass production of solid-state batteries [14][15] - With ongoing collaborations and upcoming field testing, QuantumScape is positioned to make a substantial impact in the electric mobility sector [16] Company Highlights: Nissan Motor Co. - Nissan has a long history in the EV market, launching new models like the sixth-generation Micra EV and the third-generation LEAF, which incorporates advanced features and connectivity [17][20] - The company is also advancing its autonomous driving technology, aiming to roll out an autonomous ride-share service in Japan by 2027 [19] - These developments reflect Nissan's strategy to remain competitive in a rapidly evolving market dominated by U.S. and Chinese rivals [20]

Core Viewpoint - BYD has initiated a significant price reduction for its electric vehicles (EVs) in Japan, aiming to expand its market share amid challenges in the Chinese market [1][7]. Group 1: Price Reduction Details - The price reduction ranges from 500,000 to 1,170,000 Japanese yen (approximately 24,200 to 56,700 RMB) [1][6]. - The Dolphin model will become the cheapest EV in Japan, with a new price of 2,492,000 yen (approximately 120,700 RMB), undercutting Nissan's Sakura by 100,000 yen [6][9]. - The Seal model's four-wheel drive variant will see a price drop of 1,170,000 yen, bringing its price down to 4,550,000 yen (approximately 220,500 RMB) [6][8]. Group 2: Market Context and Strategy - BYD's sales in Japan from January to July increased by 50% year-on-year, reaching 1,936 units, indicating strong performance in a growing market [1][9]. - The company is responding to intensified competition in the Chinese market, where its global new car sales grew only 0.6% in July, a significant slowdown compared to over 10% growth earlier in the year [7][9]. - The price cuts are part of a broader strategy to stimulate demand in Japan, where government subsidies can further reduce the effective price of the Dolphin to as low as 1,490,000 yen (approximately 72,200 RMB) [6][9]. Group 3: Competitive Landscape - Other automakers, such as Hyundai, have also announced price reductions for their EVs in Japan, intensifying competition in the market [11][13]. - The price war initiated by BYD in China has drawn criticism from industry groups and other car manufacturers, highlighting the challenges of maintaining profitability amid aggressive pricing strategies [8][9].

Group 1 - Nissan Motor Co., Ltd. is facing a cash shortage, leading to delays in payments to suppliers and significant global cost-cutting measures, including the elimination of 20,000 jobs, which is about 15% of its global workforce [1][10] - The company is negotiating with suppliers for extended payment terms and has offered flexible payment options to selected suppliers in the U.K. and Europe to improve cash flow for the April-June quarter [3][4][10] - As of March end, Nissan had 2.2 trillion yen in cash and equivalents but faced approximately 700 billion yen in debt maturing later in the year, with a target of 250 billion yen in cost reductions under its Re:Nissan recovery plan [6][10] Group 2 - Discussions will begin with workers at the Sunderland plant in the U.K. regarding voluntary retirement, aiming to reduce the workforce by about 250 employees, as the facility is crucial for Nissan's turnaround and future electric vehicle production [2][10] - Nissan has provided suppliers with two options for payment: defer payments at a higher interest rate or receive immediate payment from HSBC, which Nissan will reimburse later with interest [5][10]